Namer M, Toubol J, Caty A, Couette J E, Douchez J, Kerbrat P, Droz J P
Centre Antoine Lacassagne, Nice, France.
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):909-15. doi: 10.1016/0960-0760(90)90442-n.
A randomized double-blind study with a 3-yr follow-up comparing the two arms "orchiectomy + Anandron (300 mg)" vs "orchiectomy + placebo" in 125 patients with stage D prostate cancer has confirmed the beneficial effects of the combined Anandron therapy on subjective parameters and on the best objective response (NPCP criteria), although these effects were not statistically significant, but failed to detect any improvement in time-to-disease progression or survival. Comparison with the results of other trials emphasizes the urgent need to establish suitable prognostic factors by further clinical research before evaluating the benefits of individual drugs.
一项针对125例D期前列腺癌患者的随机双盲研究，对“睾丸切除术 + 阿那雄胺（300毫克）”与“睾丸切除术 + 安慰剂”两组进行了为期3年的随访，证实了阿那雄胺联合治疗对主观参数和最佳客观反应（NPCP标准）有有益影响，尽管这些影响在统计学上并不显著，但未发现疾病进展时间或生存率有任何改善。与其他试验结果的比较强调，在评估个别药物的益处之前，迫切需要通过进一步的临床研究来确定合适的预后因素。
